AstraZeneca/Daiichi's Enhertu Expansion Strategy Progresses With New Approval

Enhertu secured US FDA approval as a second-line treatment in HER2-positive breast cancer, where it is poised to become the new standard of care.

growth expansion
Enhertu is poised for growth • Source: Shutterstock

AstraZeneca PLC and Daiichi Sankyo Co., Ltd.'s Enhertu (fam-trastuzumab deruxtecan) was approved by the US Food and Drug Administration for the treatment of second-line HER2-positive breast cancer, expanding its use to an earlier line of treatment, where it is poised to become the new standard of care.

The latest approval is part of a step-wise expansion strategy for Enhertu that is expected to build the cancer drug...

More from New Products

More from Scrip